Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
4.320
-0.180 (-4.00%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Organogenesis Holdings Revenue
In the year 2024, Organogenesis Holdings had annual revenue of $482.04M with 11.29% growth. Organogenesis Holdings had revenue of $126.66M in the quarter ending December 31, 2024, with 27.10% growth.
Revenue (ttm)
$482.04M
Revenue Growth
+11.29%
P/S Ratio
1.18
Revenue / Employee
$554,710
Employees
869
Market Cap
547.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ORGO News
- 4 weeks ago - Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 - GlobeNewsWire
- 4 months ago - Organogenesis Expands Manufacturing Capacity to Support Future Growth - GlobeNewsWire
- 4 months ago - Organogenesis Commends Final LCDs - GlobeNewsWire
- 4 months ago - Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock - GlobeNewsWire
- 5 months ago - Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis - GlobeNewsWire